ciglitazone has been researched along with Endometriosis in 3 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Endometriosis: A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of a thiazolidinedione, ciglitazone, in a rat model of endometriosis." | 3.72 | Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. ( Casey, CL; Kir, M; Lebovic, DI, 2004) |
| " TZDs were first used as orally bioavailable insulin-sensitizing agents." | 1.32 | Thiazolidinedione inhibition of peritoneal inflammation. ( Chao, VA; Hornung, D; Taylor, RN; Vigne, JL; Wallwiener, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kavoussi, SK | 1 |
| Witz, CA | 1 |
| Binkley, PA | 1 |
| Nair, AS | 1 |
| Lebovic, DI | 2 |
| Hornung, D | 1 |
| Chao, VA | 1 |
| Vigne, JL | 1 |
| Wallwiener, D | 1 |
| Taylor, RN | 1 |
| Kir, M | 1 |
| Casey, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endometriosis: Immunomodulation[NCT00121953] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2005-07-31 | Withdrawn (stopped due to Due to the recent meta-analysis about CV adverse effects.) | ||
| Treatment of Endometriosis Pain With Rosiglitazone: A Prospective Phase 2 Clinical Trial[NCT00115661] | Phase 2 | 25 participants (Anticipated) | Interventional | 2005-07-31 | Terminated (stopped due to Due to the meta-analysis about CV adverse effects of rosiglitazone.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ciglitazone and Endometriosis
| Article | Year |
|---|---|
Peroxisome-proliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion.
Topics: Cell Line; Cell Proliferation; Endometriosis; Endometrium; Female; Humans; PPAR gamma; Thiazolidined | 2009 |
Thiazolidinedione inhibition of peritoneal inflammation.
Topics: Animals; Chemokine CCL5; Disease Models, Animal; Endometriosis; Female; Interleukin-1; Leukocyte Cou | 2003 |
Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis.
Topics: Animals; Endometriosis; Endometrium; Epithelial Cells; Female; Ovary; PPAR gamma; Random Allocation; | 2004 |
Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis.
Topics: Animals; Endometriosis; Endometrium; Epithelial Cells; Female; Ovary; PPAR gamma; Random Allocation; | 2004 |
Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis.
Topics: Animals; Endometriosis; Endometrium; Epithelial Cells; Female; Ovary; PPAR gamma; Random Allocation; | 2004 |
Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis.
Topics: Animals; Endometriosis; Endometrium; Epithelial Cells; Female; Ovary; PPAR gamma; Random Allocation; | 2004 |